( R )-4-propyldihydrofuran-2(3H)-one API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for ( R )-4-propyldihydrofuran-2(3H)-one API 63095-51-2?
- Description:
- Here you will find a list of producers, manufacturers and distributors of ( R )-4-propyldihydrofuran-2(3H)-one. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- ( R )-4-propyldihydrofuran-2(3H)-one
- Synonyms:
- Anhydrous
- Cas Number:
- 63095-51-2
Here you will find a list of producers, manufacturers and traders of 63095-51-2. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
( R )-4-propyldihydrofuran-2(3H)-one is a type of Bronchodilators
Bronchodilators are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) primarily used in the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). These medications function by relaxing and widening the airways in the lungs, thus facilitating easier breathing.
Bronchodilators can be classified into two main types: beta-agonists and anticholinergics. Beta-agonists, including drugs like salbutamol and formoterol, work by stimulating beta receptors in the smooth muscles of the airways, leading to their relaxation and dilation. This action allows more air to pass through the bronchial tubes and improves airflow to the lungs.
Anticholinergics, such as ipratropium bromide and tiotropium, function by blocking the action of acetylcholine, a neurotransmitter that contracts the smooth muscles in the airways. By inhibiting the effects of acetylcholine, anticholinergics promote bronchial muscle relaxation, leading to expanded airways and increased airflow.
These bronchodilator APIs are typically formulated into inhalers, nebulizers, or oral medications to deliver the active ingredients directly to the lungs. The precise dosage and administration route may vary based on the severity of the respiratory condition and the patient's individual needs.
Bronchodilators play a crucial role in managing respiratory disorders and improving patients' quality of life. They are commonly prescribed by healthcare professionals and are often used in combination with other medications, such as corticosteroids, to achieve optimal therapeutic outcomes. It is important to note that the use of bronchodilators should be carefully monitored and controlled under the guidance of a healthcare professional to ensure proper efficacy and minimize potential side effects.
